Order Article Reprints

Hatanaka T, Kakizaki S, Nagashima T, Namikawa M, Ueno T, Tojima H, Takizawa D, Naganuma A, Arai H, Sato K, et al. Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment. Cancers. 2020; 12(10):2906. https://doi.org/10.3390/cancers12102906

Hatanaka, Takeshi, Satoru Kakizaki, Tamon Nagashima, Masashi Namikawa, Takashi Ueno, Hiroki Tojima, Daichi Takizawa, Atsushi Naganuma, Hirotaka Arai, Ken Sato, and et al. 2020. "Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment" Cancers 12, no. 10: 2906. https://doi.org/10.3390/cancers12102906

Hatanaka, T., Kakizaki, S., Nagashima, T., Namikawa, M., Ueno, T., Tojima, H., Takizawa, D., Naganuma, A., Arai, H., Sato, K., Harimoto, N., Shirabe, K., & Uraoka, T. (2020). Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment. Cancers, 12(10), 2906. https://doi.org/10.3390/cancers12102906